Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London

Core Insights - Supernus Pharmaceuticals, Inc. is participating in the 2025 Jefferies Global Healthcare Conference in London on November 17, 2025, where CEO Jack A. Khattar will engage in a fireside chat [1] - The company focuses on developing and commercializing products for central nervous system (CNS) diseases [3][4] Company Overview - Supernus Pharmaceuticals specializes in treatments for various CNS disorders, including ADHD, Parkinson's disease-related dyskinesia, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [4] - The company is also developing a range of novel product candidates targeting CNS disorders [4] Investor Relations - Investors interested in meeting with company management during the conference can contact the Jefferies conference coordinator [2] - A live audio webcast of the presentation will be available, with an archived replay accessible for 60 days post-conference [2]